

EUROPASS  
CURRICULUM VITAE



**PERSONAL INFORMATION**

Name: SIMONA GURZU-PRUNDARU  
Address: George Emil Palade University of Medicine, Pharmacy, Science and Technology  
38 Ghe Marinescu Street, 540193, Targu-Mures, Romania (UMFST)  
Contact: [simona.gurzu@umfst.ro](mailto:simona.gurzu@umfst.ro); [simonagurzu@yahoo.com](mailto:simonagurzu@yahoo.com); [decanat.medicina.en@umfst.ro](mailto:decanat.medicina.en@umfst.ro)  
Nationality: Romanian  
Date of birth: 31/07/1978 Gender: Female  
Web of science ID: <https://www.webofscience.com/wos/author/record/269087>  
Web of Science ResearcherID: AAD-2710-2019; EXW-3151-2022; DVZ-8816-2022  
Publons ID: <https://publons.com/researcher/1228066/simona-gurzu>  
ORCID ID: <https://orcid.org/0000-0003-3968-5118>  
Scopus ID: <https://www.scopus.com/authid/detail.uri?authorId=23473551900>  
SciProfiles ID: <https://sciprofiles.com/profile/1227333>  
UEFISCDI/Brainmap ID: U-1700-036Q-0702 (<https://www.brainmap.ro/simona-gurzu>)  
Gogle Academic link: <https://scholar.google.com/citations?user=PVZruu0AAAAJ&hl=ro>  
Loop ID: 64628 (<https://loop.frontiersin.org/people/64628/overview>)  
Researchgate link: <https://www.researchgate.net/profile/Simona-Gurzu>  
RCA ID: <https://referencecitationanalysis.com/00000743>

**DESIRED EMPLOYMENT/**

**OCCUPATIONAL FIELD - WORK EXPERIENCE**

**Dates, Occupation, and positions held**

*The Romanian National Ministry of Education and Research*

2024-2029 **Vice-President** of the "Romanian National Board of Confirmation of PhD and habilitation titles in Medicine" (**CNATDCU**)  
From 2022- **Member in "Romanian Academy of Medical Sciences"**  
2017-2024 **Member in CNATDCU**  
2018-2024 **Projects Evaluator** - Ministry of Innovation and Scientific Research (**ANCS**)  
2019-2020/2023-2024 **Projects Evaluator** – Romanian Executive Agency for Higher Education, Research, Development, and Innovation (**UEFISCDI**)

*Romanian College of Physicians – Transylvania Branch*

2023-2029 Elected member in the Committee on Discipline

*George Emil Palade University of Medicine, Pharmacy, Sciences and Technology (PIC 930012818)*


2024-2029 **Dean - Faculty of Medicine in English - FMLE**  
**with extension in Hamburg, Germany – UMCH**  
2024 **Founder of the Digitalized Center of Morphological Sciences**  
2023-2029 Member in the Senate of the University

2023-2029 Responsible for recognition of international certificates - Faculty of Medicine in English  
 From 2021 Coordinator of the Research Center for Oncopathology and Translational Medicine (CCOMT)  
 2021 **Founder of the Research Center for Oncopathology and Translational Medicine (CCOMT)**  
 From 2021- Member of the University Committee for Research and knowledge Exchange (UCRKE)  
 2020-2024 **Vice-Dean – FMLE/UMCH**  
 2020-2024 Head of Dean's Committee of Scientific Research and of Residency  
 2020-2029 **Member in the General Scientific Council of PhD School (IOSUD/CSUD)**  
 2020-2024 Member in the Committee of Curricular activity  
 2020-2029 Member in the Council of Faculty of Medicine in English  
 2020-2022 Coordinator of COVID-related problems - Faculty of Medicine in English  
 From 2016- **Head of Department of Pathology**  
 2016-2029 Member in the Didactic Staff Council Department  
 2015-2021 *Head of the Microscopy Department - Research Center (CCAMF)*  
 From 2015- **Professor - Department of Pathology**  
 2014-2020 Responsible for scientific education of master students (preclinical research)  
 2014-2026 **Member in the Scientific Council of PhD School of Medicine (CSD)**  
 2013-2015 Associate Professor - *Department of Pathology*  
 From 2013 Scientific supervisor for PhD students (**habilitated doctor**)  
 2012 Founder of the Molecular Oncopathology Laboratory  
 2011-2013 Senior Lecturer- *Department of Pathology*  
 2006-2011 Assistant Professor (Junior Lecturer) - *Department of Pathology*

*Clinical Emergency County Hospital of Targu-Mures, Romania, Department of Pathology (PIC 900768288)*

From 2022 - Member of the Ethical Committee of Clinical Research  
 2021-2024 **Elected Member of the Ethical Council**  
 From 2021- Member of the Emergency Situations Council  
 From 2019 - Member of the HYPEC and Digestive Oncoteams  
 2017 - **Foundation of Molecular Oncopathology Laboratory**  
 From 2018 - Member of the Board of examining in-hospital deaths  
 From 2017- Member of the Board of examining the maternal deaths  
 From 2017- Member of the Medical Council  
 From 2016- **Coordinator of the activity of fellows/residents in Pathology**  
 From 2016- **Director of Clinical Department of Pathology**  
 From 2014- **Consultant GI Pathologist**  
 2010-2014 Specialist in Pathology  
 2006-2010 Fellow/Resident in Pathology

*National Institute of Oncology, Budapest, Hungary, Center of Tumors and Molecular Pathology*  
 PhD coordinator - International cotutela – 2021-2027; Visiting researcher – 2006-2016  
*Seoul University, Guro Hospital, Department of Pathology*  
 Visiting researcher – 2008-2009  
*Hamamatsu University, School of Medicine, Center of Tumors, Japan*  
 Invited Associate Professor – 2014



*Aurelios Augenzentrum Recklinghausen – Munich, Germany/University of Szeged, Hungary*

PhD coordinator - International cotutela – 2021-2026

*Semmelweis University - Budapest, Hungary*

PhD coordinator - International cotutela – 2020-2025

*Polytechnic University of Bucharest (UPB)*

PhD coordinator - National cotutela – 2021-2024

*Other internships/training programmes: 2019 – ECCO workshop, Santiago, Chile – inflammatory bowel diseases; 2017 – Tataabiocenter, Athens, Greece – next generation sequencing; 2016 - Technical University of Munich, Germany – molecular biology; 2015 – Institute of Pathology, Medical University of Graz, Austria – molecular biology; 2007 – Victor Babes University of Medicine, Timisoara, Romania – immunohistochemistry and angiogenesis.*

### **NATIONAL AND INTERNATIONAL IMPACT**

2025- ResearchGate Interest Score 1103 - higher than 93% of all ResearchGate members

2024-Included in the top 100 most cited authors – The Surgery Journal

From 2019 – Frontiers journals “loop” – scientific score higher than 99% of Frontiers members

2019 – Publons Academy mentor certificate

From June 2018 – Included in the top 4% most read authors on Academia.edu.

2017, 2018 – Outstanding Contribution in Reviewing – Elsevier Reviewer Recognition

From 2018 – Highly Influential Peer reviewer database - Baishideng Publishing Group

2018-2020 – Certification of excellence in reviewing medical papers – Spandidos Publications

From 2017 – Member of Highly Influential Scientists of Baishideng Publishing Group database.

2017 - Included in the top 25% most cited PlosOne author

2014 - First data in Europe (Medline database) about Maspin protein expression in gastric cancer (only 21 papers were published before, by authors from Asia)

2014 – Designed by Biomed central as “highly accessed published paper”.

**2012 – UNESCO-L’Oréal Laurate – For women in science programme**

2008-2012 - First data in Medline database about Mena protein expression in colorectal cancer, cervical and salivary gland lesions

### **MEMBER IN PROFESSIONAL SOCIETIES**

2021-present – *European Society of Digital and Integrative Pathology*

2021-present - *Romanian Society for Medical Oncology*

2019-present - *World Academy of Sciences*

2017-present - *American Romanian Academy of Arts and Sciences (ARA)*

2017-present - *European Chron’s and Colitis Organisation (ECCO)*

2016-present - *International Society for IHC and Molecular Morphology (ISIMm)*

2014-present - *Romanian Society for Cell Biology*

2013-present - *European Society for Medical Oncology (ESMO) – ID 318029*

2006-present - *Romanian Society for Morphology and Pathology*

*(Vice-President of Targu-Mures branch from 2019)*

2006-present - *European Society of Pathology (ESP) – Membership number 0000005589*

2016-present - member in the ESP Working Groups: Digestive Diseases, Autopsy Pathology – **reviewer for the abstracts submitted for the 35<sup>th</sup> European Congress of Pathology – Dublin, Ireland**; IT (Computational), Molecular Pathology, Dermatopathology, Soft tissue and Bone Pathology

#### MAIN ACTIVITIES AND RESPONSIBILITIES

**1. Research activity (Gastrointestinal Cancer, Epithelial mesenchymal transition, Angiogenesis, Immunohistochemistry, Molecular Pathology, Tumor histogenesis, Targeted therapy)**

**2. Methodological knowledge:** microscopy, digital pathology, In situ Hybridization, PCR analysis, NGS

**2. Clinical diagnosis in field of GI Tumor Pathology, especially colorectal and gastric cancer** (Histopathology, Immunohistochemistry, In situ Hybridization, PCR analysis, Sanger sequencing, NGS)

**3. Teaching activity:** MD students-Romanian, Hungarian and English classes, PhD students, masters' students, scientific supervisor in MD and PhD theses

**4. Administrative activities:** CEO – Clinical Department of Pathology, Vice-Dean, Research projects - coordinator, coordinator of the Research Center - CCOMT

**Fields of research:** gastrointestinal cancer, targeted oncotherapy, epithelial mesenchymal transition, angiogenesis in tumor and non-tumour lesions, tumor lymphangiogenesis, tumor histogenesis, molecular biology in colorectal/gastric cancers/melanomas (*MSI, K-ras, BRAF, p53, CDH1, HER-2, Maspin, Mena*), immunohistochemistry, In Situ Hybridization (FISH), Sanger sequencing, NGS

#### EDUCATION AND TRAINING

**Name and type of organization providing education and training:**

University of Medicine and Pharmacy of Targu-Mures, Romania

Clinical County Emergency Hospital of Targu-Mures, Romania

**Date and place:** University of Medicine and Pharmacy of Tîrgu-Mures, Romania,  
Faculty of General Medicine – MD student (1999-2005)

**Responsibilities:** - students' leadership from 1<sup>st</sup> to 6<sup>th</sup> year  
- teaching activity at Chair of Pathology starting with the 5<sup>th</sup> year

**MD thesis:** *Morphological and immunohistochemical study of colorectal carcinoma*. Scientific coordinator: Prof. Ioan Jung, Head of Pathology Department of Clinical County Emergency Hospital of Tîrgu-Mures, Romania – 2005

**Diploma:** MD (2005). University of Medicine and Pharmacy of Tîrgu-Mures

**Qualification:** Medical doctor (MD) – September 2005

Resident/Fellow in Pathology - November 2005

– passed the National Residential Exam (certificate no 107/2005)

**Date and place:** University of Medicine and Pharmacy of Tîrgu-Mures, Romania - Doctoral School  
PhD student (2005-2008)

**PhD thesis:** *Correlation between classical and modern prognostic factors, angiogenesis and lymphangiogenesis in colorectal carcinomas*. Scientific supervisors: Prof. Ioan Jung, Head of Pathology Department and of Doctoral School of University of Medicine and Pharmacy of Tîrgu-Mures, Romania and Prof. Zoltan Szentirmai, Head of Department of Pathology at National Institute of Oncology, Budapest, Hungary

**Diploma:** PhD (2008), graduated with "*summa cum laudae*"

Prize of '*Best Romanian PhD thesis in field of medicine*' (CNCSIS, 2010)

**Qualification:** MD, PhD (December 2008)



**Date:** University of Medicine and Pharmacy of Tîrgu-Mureş, Doctoral School –  
Postdoctoral researcher (2008-2013)

**Habilitation thesis:** *The role of molecular pathology in the targeted therapy of cancer*

**Diploma:** Habilitated Doctor (2013)

**Qualification:** MD, PhD, Habilitated Doctor in Medical Sciences,  
Scientific supervisor for PhD students (July 2013)

**Number of coordinating PhD students:** 2013-2025 - 9 in training and 6 PhD students get the PhD title

**Date and place:** Romanian National School of Public Health (2013-2014)

**Diploma/Qualification:** Certificate of Complementary Studies - Management of Public Health  
Romanian Ministry of Health – Certificate No C-035843/24.09.2014

#### **Name and Address of Employer**

1. George Emil Palade University of Medicine, Pharmacy, Science and Technology;  
540139 Gheorghe Marinescu 38 street, Targu-Mures, Romania Tel: (40-265) 21 31 27  
Fax: (40-265) 21 04 07 E-mail: [rectorat@umfst.ro](mailto:rectorat@umfst.ro), Website: <http://www.umfst.ro>
2. Clinical County Emergency Hospital of Targu-Mures, Romania  
540136 Gheorghe Marinescu 50 street, Targu-Mures, Romania

**Type of business or sector:** medical and academic (academic pathologist, CEO)

#### **PERSONAL SKILLS AND COMPETENCE**

**Native language:** Romanian

**Other languages:** English (Profex Certificate in Advanced Medical English-C1; Elanguest Certificate –B2)  
French, Italian

#### **Self assessment**

|         | Understanding |                    | Speaking           |                    | Writing            |
|---------|---------------|--------------------|--------------------|--------------------|--------------------|
|         | Listening     | Reading            | Spoken interaction | Oral presentation  | Writing production |
| English | high level    | high level         | high level         | high level         | high level         |
| French  | high level    | high level         | intermediate level | beginner level     | beginner level     |
| Italian | high level    | intermediate level | intermediate level | intermediate level | beginner level     |

#### **Social Skills and competences:**

Hobby: travel, poetry, painting, architecture, penguins' life

#### **Organisational skills and competence**

##### **Organizing scientific conferences (current year)**

1. The Medical Congress of Health and Education. 9-12 October 2025. Brasov, Romania - The scientific committee
2. International Congress MARISIENSIS. 22-23 May 2025. Targu-Mures, Romania
3. UMFST-UMCH Research Day. 4th of April 2025. Târgu-Mureş, Romania
4. MEDICUS - AMICUS Congress of MD students and fellows. 20-23 March 2025, Brasov, Romania – The scientific committee and Organizing committee.



## Computer skills and competences

Competent with all Microsoft Office programmes and experience with HTML, data bases access, Graph Pad InStat, digital counting with Image G NIH's computer assisted programme, MedCalc statistical software, photoshop, digital pathology

## ADDITIONAL INFORMATION

### **A. Associate/Academic Editor - Scientific Journals**

2021-2025 - Frontiers in Medicine – section Pathology. **IF 3.9** (Q1 WoS - JCI)

<https://www.frontiersin.org/journals/medicine/editors>

2022-2025- International Journal of Molecular Sciences - Topical Advisory Panel – **IF 5.6** (Q1 WoS)

2020-2025-Life - Basel – Topical Advisory Panel. **IF 3.2** (Q1 - WoS)

2022-2025 – Analytical Cellular Pathology – Hindawi - **IF 2.6** (Q2 - WoS)

2019-2025-Frontiers in Oncology – section Gastrointestinal: Colorectal Cancers. **IF 4.7** (Q2 WoS)

<https://www.frontiersin.org/journals/oncology/editors>

2014-2025-Medicine-Lippincott. **IF 1.4** (Q2 WoS)

<https://journals.lww.com/md-journal/Pages/editorialboard.aspx#BreastCancer>

2014-2025 – Acta Marisensis – seria Medica. Indexed in Scopus and EBSCO

2023-2024 – BJC Reports (partner to the British Journal of Cancer) – Springer Nature

2021-2025 - BMC Cancer – Springer Nature - **IF 3.8** (Q2 - WoS)

2022- Frontiers in Immunology. **IF 7.3** (Q1 web of science - WoS)

2014-2021 – BMC Musculoskeletal Disorders. **IF 1.879** (Q2 WoS-2021)

### **B. Guest Editor-Scientific Journals**

2025 – Current Issues in Molecular Biology – Special Issue – "Future Challenges of Targeted Therapy of Cancers. Second edition". **IF 2.8** (Q3 WoS)

2025 – Oncology Research – Special issue - Gastroenteropancreatic Tumors: From Basic Research to Therapeutic Approach. **IF 2** (Q3 – WoS)

2024/2025 – Life – Special Issue - "Helicobacter pylori" **IF 3.2** (Q1 WoS)

2023-2025 – International Journal of Molecular Sciences – Special Issue "Cardiovascular Diseases: Histopathological and Molecular Diagnostics" - **IF 5.6** (Q1 WoS)

2024 – Cancers – Special Issue " Histopathology and Diagnosis of Gastrointestinal Tumors" – **IF 5.2** (Q2 - WoS)

2024 – Applied Sciences – Special Issue "Advances in Gastrointestinal Cancer Research: A Molecular and Biological Perspective" – **IF 2.7** (Q2 - WoS)

2024 – Current Issues in Molecular Biology – Special Issue – "Future Challenges of Targeted Therapy of Cancers II". **IF 3.1** (Q3 WoS). **IF 3.1** (Q3 – WoS)

2023/2024 – International Journal of Molecular Sciences – Special Issue "The carcinogenetic potential of Human Papilloma Virus: from experimental studies to targeted therapy" - **IF 5.6** (Q1 WoS)

2023/2024 - Frontiers in Bioscience-Landmark – Special Issue – "Gastrointestinal cancer: Pathogenesis, carcinogenesis and targeted therapies". **IF 3.1** (Q3 – WoS)

2023/2024 – Current Issues in Molecular Biology – Special Issue – "Future Challenges of Targeted Therapy of Cancers". **IF 3.1** (Q3 WoS)

2023 – International Journal of Molecular Sciences – Special Issue – "Advanced Research on Biomarkers in Gastrointestinal Cancer". **IF 5.6** (Q1 WoS)

2023 – International Journal of Molecular Sciences – Special Issue – "Future Challenges of Targeted Therapy of Cancers". **IF 5.6** (Q1 WoS)



2023-Life - Basel – Special Issue – “Pediatric Gastroenterology Research” **IF 3.253** (Q2 - WoS)

2022 – Gastrointestinal Disorders – Special issue - "Diagnostics, Pathology and Biomarkers of Gastrointestinal Neoplasms". **IF 0.7**

2021/2022 – Journal of Oncology – Special Issue – “Colorectal Cancer: from Molecular Genetics to Diagnosis and Therapy”. **IF 4.375** (Q2 WoS) <https://www.hindawi.com/journals/jo/si/965785/>

2022 – International Journal of Molecular Sciences – Special Issue - "Molecular Diagnostics, Pathology and Biomarkers of Gastrointestinal Neoplasms". **IF 5.923** (Q1 WoS) [https://www.mdpi.com/journal/ijms/special\\_issues/molecular\\_diagnostics\\_biomarkers\\_gastrointestinal\\_neoplasms](https://www.mdpi.com/journal/ijms/special_issues/molecular_diagnostics_biomarkers_gastrointestinal_neoplasms) 12 published papers

2020/2021 – Life-Basel – Special Issue - “Serum and tissue biomarkers in Cancer: A Translational Approach” **IF 3.817** (Q2 WoS)

2020/2021 – Journal of Oncology – Special Issue – “Gastric Cancer: from Molecular Genetics to Diagnosis and Therapy”. **IF 4.375** (Q2 WoS) <https://www.hindawi.com/journals/jo/si/425940/>

2019/2020 - BioMed Research International. Special Issue in section Oncology - “Tumor Cell Plasticity: From Tumorigenesis to Metastasis”. **IF 3.411** (Q2 WoS)

### **C. Topic Editor-Scientific Journals**

2025 - Frontiers in Oncology – Special Issue/Research Topic in section Gastrointestinal Cancers: Colorectal Cancer – “National Colorectal Cancer Awareness Month 2025: Current Progress and Future Prospects on Colorectal Cancer Prevention, Diagnosis and Treatment”. Co-edited with Alessandro Passardi – IRCCS, Medola, Italy; Rocco Ricciardi – Harvard Medical School; David Gibbons – Dublin, Ireland. **IF 3.5** (Q2 WoS)

2025 - Frontiers in Oncology – Special Issue/Research Topic in section Gastrointestinal Cancers: Interplay between Environmental Drivers and Genetic or Epigenetic Predispositions on Gastrointestinal Cancer Evolution. Co-edited with Zhang Shaosen – Center for National Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China; Xudong Huang - Sun Yat-sen University Cancer Center (SYSUCC) Guangzhou, China and Caihong Wang Peking University People's Hospital Beijing, China. **IF 3.5** (Q2 WoS)

2024 - Frontiers in Pharmacology – Special Issue/Research Topic in section Pharmacology of Anti-Cancer Drugs – “Immune Checkpoints Regulatory Mechanisms and Immunotherapy Strategies in Gastrointestinal Tumors”. Co-edited with Rongxin Zhang and Qing Xi - Guangdong Pharmaceutical University - Guangzhou, China. **IF 5.6** (Q1 WoS)

2024 - Frontiers in Oncology – Special Issue/Research Topic in section Gastrointestinal Cancers – “Advanced molecular targets in the diagnosis and treatment of gastrointestinal cancer: Vol II”. **IF 3.5** (Q1 WoS)

2022 - Frontiers in Oncology – Special Issue/Research Topic in section Gastrointestinal Cancers – “Detection and characterization of gastrointestinal (early) cancer”. Co-edited with Andrej Wagner - Paracelsus Medical University - Salzburg, Austria; Valeria Barresi -University of Verona, Italy; and Yuming Jiang - Stanford University, United States. **IF 6.244** (Q2 WoS)

2021 - Frontiers in Oncology – Special Issue – “Advanced molecular targets in the diagnosis and treatment of gastrointestinal cancer”. **IF 6.244** (Q2 WoS)

### **D. Member in Editorial Board-Scientific Journals**

2024-2025 - BMC Cancer – Springer Nature - **IF 3.8** (Q2 - WoS)

2020-2025 – Life-Basel – Reviewer board. **IF 3.2** (Q1- WoS)

2021 -2025 - Pathology Research and Practice - Elsevier - **IF 2.8** (Q2 - WoS)

2022-2025 - Oncology Letters. **IF 2.5** (Q3 web of science)

2023-2025 – Cancer Informatics – Editorial review board. Sage. **IF 2.4** (Q2 - WoS)

2021-2025 - Romanian Journal of Morphology and Embryology. **IF 1.2** (Q4 web of science)

2012-2025 - World Journal of Clinical Cases. **IF 1** (Q3 web of science)

2016-2025 – BMJ Case Reports. **IF 0.6** (Q3 web of science)

2023-2025 – Healthcare in Low-Resource Settings. **IF < 0.**

2022-2025 – Journal of Exploratory Research in Pharmacology. Indexed in Index Copernicus

2019-2025 - World Journal of Gastrointestinal Pathophysiology. Indexed in PubMed

2019-2025 - Current Drug Research Reviews. Indexed in PubMed

2019-2025 - World Academy of Sciences Journal. Spandidos Publications. Indexed in Scopus (Elsevier)

2017-2025-Medicinski Glasnik-Indexed in Scopus

2015-2025 - Journal of Dermatological Research – Indexed in Google Scholar

2015-2023 – Cancer Translational Medicine - Wolters Kluwer- Indexed in EBSCO

2017-2018-Current Chemical Genomics & Translational Medicine-Indexed in PubMed

2016-2017-New Horizons in Clinical Case Reports – Indexed in Scopus

2016-2017 – Clinics in Oncology – Indexed in Indexed in ICMJE, Publons, Crossref

2013-2017 – Edorium Journal of Pathology – Indexed in J-Gate

2013-2017 – Global Journal of Oncologists – Savvy Press – Indexed in DRJI

2010-2011 - Journal of Cancer Research and Experimental Oncology

#### E. PUBLICATIONS

|                                                                                     |                                                                                   |
|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Papers in extenso published in WoS-indexed journals.....                            | 174                                                                               |
| Papers in extenso published in BDI-indexed journals.....                            | 38                                                                                |
| Other papers published in extenso .....                                             | 19                                                                                |
| Papers in abstract published in WoS-indexed journals.....                           | 103                                                                               |
| Papers in abstract published and presented at other international conferences.....  | 61                                                                                |
| Papers in abstract published and presented at national conferences.....             | 205                                                                               |
| Books and chapters published in books .....                                         | 26                                                                                |
| <b>Total Impact factor (IF) from papers in extenso .....</b>                        | <b>362.22</b>                                                                     |
| <b>Total Influence score from papers in extenso.....</b>                            | <b>147.37</b>                                                                     |
| <b>Total Journal citation indicator (JCI) from papers in extenso-2017-2025.....</b> | <b>57.74</b>                                                                      |
| <b>Total Impact factor from abstracts .....</b>                                     | <b>537.33</b>                                                                     |
| <b>Total Influence score from abstracts.....</b>                                    | <b>181.42</b>                                                                     |
| <b>Citations.....</b>                                                               | <b>2677 - Google Scholar</b>                                                      |
| <b>Hirsh-index.....</b>                                                             | <b>28-Google Scholar/23-ResearchGate/21-web of science/21-Scopus/i10-index 88</b> |

#### F. FOREIGN STUDY TRIPS (SCHOLARSHIPS)

1. **Munich, Germany**, June – July 2016 - UEG (United European Gastroenterology) Basic Science Course
2. **Hamamatsu- Japan**, July – August 2014 – Hamamatsu University, School of Medicine, Department of Pathology – Invited Associate Professor
3. **Budapest- Hungary**, February 2013 – National Institute of Oncology, Department of Molecular Biology
4. **Budapest- Hungary**, November 2010/July-August 2011/February 2012/July-August 2012 – National Institute of Oncology, Department of Molecular Biology - project PD 504/2010.
5. **Seoul, South Korea**, November 2008/May -June 2009 – Seoul University, Guro Hospital - project

09/30.05.2008, ANCS, Romania.

6. **Pecs-Hungary**, April 2009 – University of Pecs, Faculty of Medicine, Department of Public Health - project 6CB/2008, ANCS, Romania.
7. **Budapest- Hungary**, August – September 2008/February 2009 – National Institute of Oncology, Department of Molecular Biology - project 7CB/2008, ANCS, Romania
8. **Budapest- Hungary** July 2008 – National Institute of Oncology, Department of Molecular Biology - project TD 355/2008, CNCSIS, Romania
9. **Budapest- Hungary**, August 2007 – National Institute of Oncology, Department of Molecular Biology - project TD 505/2007, CNCSIS, Romania
10. **Budapest- Hungary**, October 2006 – National Institute of Oncology, Department of Molecular Biology - project 227/2006, CEEX, Romania.

## **G. SCIENTIFIC PROJECTS**

### ***G.1. HEAD/TEAM COORDINATOR - NATIONAL GRANTS***

1. **2024** – MC, UEFISCDI – Code: PN-IV-P2-2.2-MC-2024-0605. Microsatellite instability status and PDL-1 expression in liposarcomas.
2. **2024** – MC, UEFISCDI – Code: PN-IV-P2-2.2-MC-2024-0785. ARSB, Maspin and TP53 gene expression in colorectal carcinoma.
3. **2019** - MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2019-2538. Plasmacytoid carcinomas of the stomach: the immunoprofile highlights the potential targeted therapy of these rare histological variants
4. **2019** – MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2019-2145. Scholarship for participation at the 63rd ECCO Educational workshop.
5. **2018-2022** – Proiect Complex de Cercetare de Frontieră – Romanian National Authority for Scientific research - PN-III-P4-ID-PCCF-2016-0006. GRAPHSENGASTROINTEST/Graphene-based stochastic sensors for molecular diagnosis of upper gastro-intestinal cancer
6. **2018** – MC, UEFISCDI - PN-III-P1-1.1-MC-2018-0233 - Bit's 9th annual World DNA And Genome Day. Molecular classification of carcinomas of the gastrointestinal tract – Practical issues.
7. **2017** – MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2017-1950 – No 536/18.12.2017. Gastric Burkitt lymphoma: a case report and literature review.
8. **2017** – MC, UEFISCDI – Code: PN-III-P1-1.1-MC-2017-0197 – No 524/18.12.2017. 22<sup>nd</sup> World Congress on advances in oncology and 20th International Symposium on molecular medicine. Pitfalls in evaluation of gastrointestinal specimens: metastases mimicking primary tumors.
9. **2014-2020** - MECS-ANCSI. POC-A1-A1.1.4-E-2015. No 50/2016. ID: P\_37\_673. Technologies of tissue engineering for cardiac valve regeneration. VALVE-REGEN. Coordinator of the team of Pathology
10. **2014-2016** - UMFTGM-PO-CC-02-F01: Molecular particularities of early-staged and advanced-gastric cancer, emphasized in surgical and biopsic specimens of patients from Eastern Europe and Japan
11. **2012-2013** - Unesco-L'Oreal: Initiation of targeted therapy in Romanian patients diagnosed with colorectal cancer. National fellowship
12. **2010-2012** - PD, 504/2010, UEFISCDI: Molecular classification of colorectal cancers and testing of K-ras mutations, mandatory for targeted therapy
13. **2008** - TD, 355/2008, CNCSIS – The correlation between prognostic and predictive factors, angiogenesis, lymphangiogenesis and microsatellite instability in colorectal carcinomas
14. **2008** - MC, 85/2008, CNCSIS - The CD31, Endoglin and VEGF expression in non-metastatic

colorectal carcinomas


15. 2007 - MD, 33/2007, CNCSIS: Angiogenesis and lymphangiogenesis in colorectal tumors
16. 2007 - TD, 550/2007, CNCSIS: Classical and modern prognostic factors in colorectal carcinomas

### **G.2. MEMBER IN INTERNATIONAL GRANTS**

1. 2008-2009 – Romania-South Korea: 09/2008, ANCS: Angiogenesis in acute respiratory distress syndrome
2. 2008-2009 - Romania-Hungary, Pecs: 06/2008, ANCS: Mena immunoexpression in benign, premalignant and malignant epithelial lesions. NEOMENA.
3. 2008-2009 - Romania-Hungary, Budapest: 07/2008, ANCS: Molecular classification of carcinomas and lymphomas using genetic methods in order to anticipate the results of treatment and to make an individualizing oncotherapy. NEOLIMF.

### **G.3. MEMBER IN NATIONAL GRANTS**

1. 2024-2025 – PNRR project. Role of HIV-1 matrix protein p17 variants in lymphomagenesis: development of new diagnostic tools and therapeutic approaches.
2. 2022-2023 - INEXT - PNRR project for digital development of the professions of the future – Foundation of the Digital Center of Medical Morphological Sciences
3. 2022-2023 – POCU/826/4/9/138603. Prevention, diagnosis, and therapy of cervical cancer in early stages.
4. 2021-2023 – PN-III-P4-ID-PCE2020-1540. Novel C-reactive protein inhibitors and dissociation blockers for therapeutic use in cardiovascular disease
5. 2020-2022 - POS-UMFTGM-CC-19: Parietex mesh particularities
6. 2017-2018 – Hungarian Academy of Science 136/2017 – The epithelial-mesenchymal transition in tumors of the gastrointestinal tract.
7. 2017-2018 - Sapientia Hungariae Alapitvány – “A Collegium Talentum” programme – contract 6677/2017
8. 2016-2020 - MECS-ANCSI. POC-A1-A1.1.4-E-2015. No 51/2016. ID: P\_37\_674. C-reactive protein therapy for stroke-associated dementia. SAD-CRP
9. 2015-2016 - Biosintex SRL. 11379/2015. Analysis of clinical and paraclinical parameters used for improvement of diagnostic and therapeutical management of patients with coxartrosis.
10. 2013-2016 - PN-II-ID-PCE-2012-4-0133 „Neuroprotection and angiogenesis: new molecular factors and delivery systems with potential therapeutic application”.
11. 2014-2016 - POS 2013. Foundation of the Advanced Research Center in field of Pharmaceutical and Medical Research, at University of Medicine and Pharmacy of Tirgu-Mures, Romania. CCAMF.
12. 2014-2015 - POSDRU/159/1.5/S/136893. Identification of the particularities of hereditary and sporadic diffuse gastric cancer through molecular and immunohistochemical examinations. Mentor.
13. 2014-2015 - Treepharm S.A. 1699/2014. The advantages and disadvantages of the ligasurterm techniques.
14. 2013-2015 - POS-UMFTGM-CC-13-01-V01, 15/2013 – Standardization of multimodal therapy of gastric cancer, correlating the sentinel node status with the surgical technique and HER-2 gene amplification



15. **2012-2016** - PN-II-ID-PCCE-2011-2-0036: Stem cell seeded collagen scaffolds for heart valve replacement; cod PN-II-ID-PCCE-2011-2-0036.
16. **2010-2013** - POSDRU/89/1.5/S/60782
17. **2008-2011** - 136/2008, CNCSIS: Mechanisms of cellular signaling implied in angiogenesis induced by Acute Respiratory Distress Syndrome (ARDS).
18. **2008-2011** - 1173/2009, CNCSIS: Pathogenic mechanisms implied in developing of insuliniresistance appeared in infection with Hepatitis C virus. HEPINS.
19. **2007-2008** - 41 GR/2007, CNCSIS: Evaluation of metastasis from sentinel lymph node of breast carcinomas through interdisciplinary and multicentric studies in order to develop a new staging and new treatment
20. **2007-2008** - CP-I/13.09.2007, ANCS: Standardization of European detection and early diagnosis of cervical carcinoma and premalignant cervical lesions. EUROGYNPATh
21. **2007-2010 - Partnership** between Universities of Medicine and Pharmacy of Targu-Mures and Timisoara, Romania. 41-054/2007, ANCS: Prognostic and therapeutic value of tumoral lymphangiogenesis. Anatomico-clinic and experimental study in solid malignant tumors.
22. **2007-2008** - 227/2006, CEEEX: Modern methods in diagnosis and research, immunohistochemistry, molecular biology and quality control. MEMODIC.

#### **G.4. EVALUATOR OF NATIONAL GRANTS**

1. **2024** - Romanian Executive Agency for Higher Education, Research, Development, and Innovation (UEFISCDI) - PED competition
2. **2023** - UEFISCDI - PNRR-Dotari-2023
3. **2018-2024** – Romanian National Ministry for Innovation and Scientific Research (ANCS). Funding of Excellency in research, development, and innovation (CDI) - Subprogramme 1.2 – Institutional performance.
4. **2016-2024** – L’Oreal and UNESCO-Romanian branch. Competition for national fellowship “Women in science”.
5. **2019, 2024** - UEFISCDI. Competition of research collaboration between Romania and France. UEFISCDI PN-III-P3-3.1-PM-RO-FR-2019. Certificate no 25/18.04.2019
6. **2017** – Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. Internal competition for the team grant award. Certificate no 3407/14.03.2017.

#### **H. PROFESSIONAL SCIENTIFIC AWARDS (current year)**

1. **2024** – Award for didactic excellence in the teaching process – The League of the MD students – G.E. Palade UMPHST, Targu-Mures, Romania
2. **2024** – The Women Employers Romanian National Gala – Award for the excellence in academic and scientific research in field of oncology

#### **I. ALUMNI**

2022 – Aspen Public Service Leadership Program

2012 – The L’Oreal programme „For Women in Science” – winner at the section Life Sciences

Date,  
04/29/2025

Signature,  
Prof. Dr. Habil. Simona Gurzu-Prundaru